Is Buying Cascadian Therapeutics Inc (USA) (CASC) Here a Winning Strategy?

September 17, 2017 - By Clifton Ray

The stock of Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) is a huge mover today! The stock increased 4.09% or $0.15 on September 15, reaching $3.82. About 847,604 shares traded or 164.62% up from the average. Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) has declined 30.85% since September 17, 2016 and is downtrending. It has underperformed by 47.55% the S&P500.
The move comes after 9 months positive chart setup for the $193.11 million company. It was reported on Sep, 17 by We have $4.13 PT which if reached, will make NASDAQ:CASC worth $15.45 million more.

Analysts await Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) to report earnings on November, 6. They expect $-0.28 earnings per share, up 48.15 % or $0.26 from last year’s $-0.54 per share. After $-0.30 actual earnings per share reported by Cascadian Therapeutics Inc (USA) for the previous quarter, Wall Street now forecasts -6.67 % EPS growth.

More notable recent Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) news were published by: which released: “BRIEF-Mark Lampert says resigning from Cascadian Therapeutics’ board” on January 17, 2017, also with their article: “Cascadian Therapeutics Appoints Dr. Marc L. Lesnick as Senior Vice President …” published on January 04, 2017, published: “Cascadian Therapeutics to Report Second Quarter 2017 Financial Results on …” on August 01, 2017. More interesting news about Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) were released by: and their article: “Cascadian Therapeutics: Worth Much More Than The Present Share Price” published on March 23, 2017 as well as‘s news article titled: “Cascadian Therapeutics Announces Positive Regulatory Update for Tucatinib in …” with publication date: July 11, 2017.

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The company has market cap of $193.11 million. The Firm focuses on the development of therapeutic products for the treatment of cancer. It currently has negative earnings. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor 2 inhibitor.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: